GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shan Dong Kexing Bioproducts Co Ltd (SHSE:688136) » Definitions » Peter Lynch Fair Value

Shan Dong Kexing Bioproducts Co (SHSE:688136) Peter Lynch Fair Value : N/A (As of Jun. 02, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shan Dong Kexing Bioproducts Co Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Shan Dong Kexing Bioproducts Co's Peter Lynch Fair Value or its related term are showing as below:



SHSE:688136's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Biotechnology industry.
Industry Median: 1.7
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Shan Dong Kexing Bioproducts Co Peter Lynch Fair Value Historical Data

The historical data trend for Shan Dong Kexing Bioproducts Co's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shan Dong Kexing Bioproducts Co Peter Lynch Fair Value Chart

Shan Dong Kexing Bioproducts Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial - - - - -

Shan Dong Kexing Bioproducts Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Shan Dong Kexing Bioproducts Co's Peter Lynch Fair Value

For the Biotechnology subindustry, Shan Dong Kexing Bioproducts Co's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shan Dong Kexing Bioproducts Co's Price-to-Peter-Lynch-Fair-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shan Dong Kexing Bioproducts Co's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Shan Dong Kexing Bioproducts Co's Price-to-Peter-Lynch-Fair-Value falls into.



Shan Dong Kexing Bioproducts Co Peter Lynch Fair Value Calculation

Shan Dong Kexing Bioproducts Co's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-1.01
=N/A

Shan Dong Kexing Bioproducts Co's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was ¥-1.01.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Shan Dong Kexing Bioproducts Co  (SHSE:688136) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Shan Dong Kexing Bioproducts Co's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=19.02/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shan Dong Kexing Bioproducts Co Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Shan Dong Kexing Bioproducts Co's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Shan Dong Kexing Bioproducts Co (SHSE:688136) Business Description

Traded in Other Exchanges
N/A
Address
No. 2666, Chuangye Road, Mingshui Development Zone, Zhangqiu District, Shandong Province, Jinan, CHN, 250200
Shan Dong Kexing Bioproducts Co Ltd formerly Kexing Biopharmaceutical Co Ltd is an innovative biopharmaceutical company. It is engaged in the production and sales of recombinant protein drugs and probiotics. The company use the drugs in the fields of antiviral, hematology, tumor and immunity, and degenerative diseases.
Executives
Wang Xiao Qin Directors, senior managers
Cui Ning Directors, senior managers
Ma Hong Jie senior management
Shao Ke senior management
Deng Xue Qin Director
Zhao Yan Qing Directors, senior managers

Shan Dong Kexing Bioproducts Co (SHSE:688136) Headlines

No Headlines